Seamless Phase II/III Trials in Orphan Indications
Seamless Phase II/III Trials in Orphan Indications Accelerating Rare Disease Drug Development with Seamless Phase II/III Trial Designs Introduction: Why Seamless Designs Matter in Rare Diseases Traditional clinical trials follow a linear sequence—Phase I to Phase III—often resulting in delays and duplication of efforts. For orphan indications, where patient populations are scarce and unmet needs…
Read More “Seamless Phase II/III Trials in Orphan Indications” »